RT-PCR and in situ hybridization are different methods to evaluate HER2 in tumor material, and some discordant cases were present; for example, some tumors in the low ERBB2 mRNA group had intermediate levels of HER2 amplification group and vice versa. The gene discussed is ERBB2; the disease is neoplasm.